Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (5) , 357-369
- https://doi.org/10.2165/00019053-200321050-00007
Abstract
Objective: To determine the effect of age, disease severity and compliance on the annual primary-care cost of managing patients with asthma initially on British Thoracic Society British Guidelines on Asthma Management (BGAM) treatment steps 2/3 over 5 years. Design and setting: A modelling study performed from the perspective of the UK’s National Health Service (NHS). Study participants and interventions: A data set was created comprising 4519 patients with asthma in the DIN-link database who were prescribed twice-daily inhaled corticosteroids and who were on steps 2/3 between 1 January and 31 December 1993. These patients were followed over 5 years. Methods: Asthma-related primary-care resource utilisation data obtained from the DIN-link database were stratified by patients’ age, compliance and BGAM treatment step. Unit costs at 1999–2000 prices were applied to the resource use estimates to determine the mean annual cost per patient. Main outcome measures and results: High compliance with inhaled corticosteroids was not associated with a reduction in use of other primary-care resources, although the ratio of the number of prescriptions for inhaled corticosteroids to that for short-acting β2-agonists increased, suggesting that patients’ asthma was better controlled. Overall, the primary-care cost of managing a patient starting on steps 2/3 was found to be most strongly influenced by whether that patient moved onto steps 4/5 or continued to be managed on the same treatment step. If a patient continued to be managed at steps 2/3, costs were influenced in descending order of impact by compliance, previous BGAM step and the patient’s age. Conclusions: Better compliance with inhaled corticosteroids is likely to lead to better asthma control and fewer asthma attacks. Notwithstanding this, increasing compliance is likely to increase primary-care costs. Consequently increasing healthcare expenditure may be the inevitable consequence of improving asthma control.Keywords
This publication has 16 references indexed in Scilit:
- Developing Guidance for Budget Impact AnalysisPharmacoEconomics, 2001
- Economic Impact of Tibolone Compared with Continuous-Combined Hormone Replacement TherapyPharmacoEconomics, 2000
- Risk factors and costs associated with an asthma attackThorax, 2000
- A cost analysis on the pattern of asthma prescribing in the UKEuropean Respiratory Journal, 1999
- Should the corticosteroid to bronchodilator ratio be promoted as a quality prescribing marker?Public Health, 1999
- Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B MonotherapyPharmacoEconomics, 1999
- Drug Treatment of Asthma in the 1990sDrugs, 1999
- Compliance With National Asthma Management Guidelines and Specialty CareArchives of internal medicine (1960), 1998
- Is the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissionsBMJ, 1996
- Prescribing and hospital admissions for asthma in east LondonBMJ, 1996